Drug Landscape ›
Depo-Medrone ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 158
Most-reported reactions
Malaise — 33 reports (20.89%) Confusional State — 20 reports (12.66%) Diarrhoea — 19 reports (12.03%) Nausea — 14 reports (8.86%) Vomiting — 14 reports (8.86%) Pruritus — 13 reports (8.23%) Lethargy — 12 reports (7.59%) Dizziness — 11 reports (6.96%) Dyspnoea — 11 reports (6.96%) Erythema — 11 reports (6.96%)
Source database →
Depo-Medrone in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Depo-Medrone approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Depo-Medrone in United States?
Keele University is the originator. The local marketing authorisation holder may differ — check the official source linked above.